UFP Technologies (NasdaqCM:UFPT) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold UFP Technologies to reach your target.
Based on historical returns, we believe that UFP Technologies can grow its free cash at a rate of about 7%. That's positive!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| UFPT Price (UFP Technologies stock price per share) |
$290.85 | |
|
|
UFPT Fair Price (based on intrinsic value) |
$58.74 |
| UFPT Safety Price (based on a variable margin of safety) | $35.24 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 50% higher than other Healthcare stocks | |
| PE Ratio versus Industry | 228% higher than other Medical Devices stocks | |
| Cash Yield | 0.07% | |
| Free Cash Flow Jitter | 89% | |
No open-market insider buys or sells are recorded for the last 12 months.
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 913,963 shares shorted. With 7,479,947 shares available for purchase and an average trading volume over the past 10 trading days of 78,600, it would take at least 11.6 days for all of the short holders to cover their shorts.
What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2009 | 914156 | 10.3 |
| 2010 | 914156 | 10 |
| 2011 | 914156 | 9.2 |
| 2012 | 914156 | 11.3 |
| 2013 | 914156 | 11.1 |
| 2014 | 914156 | 3.5 |
| 2015 | 914156 | 2.4 |
| 2016 | 914156 | -1.5 |
| 2017 | 914156 | 6.9 |
| 2018 | 914156 | 10.9 |
| 2019 | 914156 | 22.3 |
| 2020 | 914156 | 18.4 |
| 2021 | 914156 | 8 |
| 2022 | 914156 | 10.8 |
| 2023 | 914156 | 33.4 |
| 2024 | 914156 | 57.9 |
| 2025 | 914156 | 84 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 13 fiscal years from 2013 to 2025 with positive net income, operating cash flow totaled $376 million against net income of $321 million, or 1.17 times.
In 2025, operating cash flow was 1.35 times net income, compared with 1.50 times for the earliest three years (2013 to 2015).
In 2024, capital expenditures were $9.7 million, 14.5% of operating cash flow of $66.6 million, which leaves an estimated $56.9 million after capex. Across the 12 years with reported capex, it averaged 37.8% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2013 | 11.3 | 16.1 | 5.8 | 1.43 |
| 2014 | 7.6 | 11.1 | 13.4 | 1.47 |
| 2015 | 7.6 | 12.5 | 15.7 | 1.65 |
| 2016 | 8 | 9.3 | 7.2 | 1.17 |
| 2017 | 9.2 | 17.5 | 10.4 | 1.90 |
| 2018 | 14.3 | 21.3 | 5.4 | 1.49 |
| 2019 | 19.8 | 31.2 | 5.8 | 1.58 |
| 2020 | 13.4 | 25 | 4.4 | 1.87 |
| 2021 | 15.9 | 14.3 | 5.4 | 0.90 |
| 2022 | 41.8 | 17.7 | 13.8 | 0.42 |
| 2023 | 44.9 | 41.3 | 10.5 | 0.92 |
| 2024 | 59 | 66.6 | 9.7 | 1.13 |
| 2025 | 68.3 | 91.9 | not reported | 1.35 |
How to read this: earnings and margins.
Revenue was $99.2 million in 2009 and $603 million in 2025, a compound annual growth rate of 11.9% over 16 years.
Revenue rose 19.5% from 2024 to 2025.
Our estimated free cash flow was $84 million in 2025, 13.9% of revenue. In 2009 the estimated margin was 10.4%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2009 | 99.2 | 10.3 | 10.4% |
| 2010 | 121 | 10 | 8.3% |
| 2011 | 127 | 9.2 | 7.3% |
| 2012 | 131 | 11.3 | 8.6% |
| 2013 | 139 | 11.1 | 7.9% |
| 2014 | 139 | 3.5 | 2.5% |
| 2015 | 139 | 2.4 | 1.7% |
| 2016 | 146 | -1.5 | -1.1% |
| 2017 | 148 | 6.9 | 4.7% |
| 2018 | 190 | 10.9 | 5.7% |
| 2019 | 198 | 22.3 | 11.3% |
| 2020 | 179 | 18.4 | 10.3% |
| 2021 | 206 | 8 | 3.9% |
| 2022 | 354 | 10.8 | 3.1% |
| 2023 | 400 | 33.4 | 8.3% |
| 2024 | 504 | 57.9 | 11.5% |
| 2025 | 603 | 84 | 13.9% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $20.3 million against total liabilities of $231 million, or 8.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 35.3% of total assets in 2025, compared with 27.7% in 2010, an increase of 7.6 percentage points.
Stockholders equity was $424 million in 2025, compared with $50.2 million in 2010, a rise of 743.9%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 15.0% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2010 | 69.5 | 22.1 | 19.3 | 50.2 |
| 2011 | 79.7 | 29.8 | 17.7 | 62 |
| 2012 | 98.6 | 33.5 | 25.4 | 73.3 |
| 2013 | 105 | 37.3 | 19.3 | 85.6 |
| 2014 | 113 | 34.1 | 17.6 | 95 |
| 2015 | 120 | 29.8 | 16.1 | 104 |
| 2016 | 128 | 31.4 | 14.9 | 113 |
| 2017 | 138 | 38 | 14.5 | 124 |
| 2018 | 190 | 3.2 | 49.1 | 140 |
| 2019 | 189 | 3.7 | 26.8 | 162 |
| 2020 | 203 | 24.2 | 26.3 | 177 |
| 2021 | 334 | 11.1 | 140 | 194 |
| 2022 | 378 | 4.5 | 141 | 238 |
| 2023 | 404 | 5.3 | 118 | 286 |
| 2024 | 629 | 13.4 | 286 | 343 |
| 2025 | 655 | 20.3 | 231 | 424 |
How to read this: discounted cash flow, intrinsic value.
At today's price of $290.85, the price is above what our model can produce for average free cash flow growth between -30 and 60 percent a year, so no implied growth rate is shown. Our model assumes 7.0 percent a year for this stock. This is not a forecast of growth or a price target.
The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.
The model starts from the company's average free cash flow of $1.6 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.
The baseline is the company's average free cash flow, and cyclical companies can mislead it.
| Case | Price per share | Average annual free cash flow growth |
|---|---|---|
| 20 percent below the current price | $232.68 | above range |
| Current price | $290.85 | above range |
| 20 percent above the current price | $349.02 | above range |
| Our model (stored fair price) | $58.74 | 7.0% |
Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.
At $290.85, UFP Technologies trades above our fair value estimate of $58.74.
Of the 17 fiscal years we can see for UFP Technologies under its current filer, 16 show positive free cash flow.
Free cash flow from the first three years of data averaged $9.9 million, and from the last three $58.4 million: a sharp rise.
Free cash flow is volatile from year to year, with a variability measure of 89%.
Our value investing guide explains how to test these numbers against the filings themselves.
No dividend yield is recorded for UFP Technologies in our data.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 50% above the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 228% above the average for stocks in the Medical Devices industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Medical Devices industry, the ones closest in market capitalization to UFP Technologies, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| UFP Technologies (UFPT) | 2,253 | 29.7 | - | 0.1% | 395% above |
| LeMaitre Vascular (LMAT) | 1,684 | 27.1 | 1.3% | - | 328% above |
| CONMED Corporation (CNMD) | 1,382 | 19.2 | - | 5.6% | 35% below |
| IRadimed Corporation (IRMD) | 1,036 | 43.3 | 1.0% | - | 995% above |
| Tactile Systems Technology (TCMD) | 573 | 24.9 | - | - | 162% above |
| InfuSystem Holdings (INFU) | 287 | 32.6 | - | - | 402% above |
| Utah Medical Products (UTMD) | 198 | 20.8 | 1.7% | 6.7% | 75% below |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 914156.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: UFPT annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does UFP Technologies have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to UFPT: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
How Does Portfolio Churning Affect Your Returns?
Insider Buying as a Conviction Signal
What is Market Capitalization?
What is Cash Return on Invested Capital?